Non-Core Brands Downside Contribute to ANI Pharma's (ANIP) Revenue Miss; Roth Capital Reiterates Buy
-
Roth Capital Downgrades ANI Pharmaceuticals (ANIP) to Neutral
-
Pre-Open Stock Movers 3/5: (FCEL) (ARWR) (SWHC) Higher; (XOMA) (HCI) (CSIQ) Lower (more...)
-
ANI Pharma (ANIP) Prices 1.4M Common Stock Offering at $31/Share
-
After Hours Stock Movers 3/4: (BV) (SWHC) (AVAV) Higher; (XOMA) (CHEF) (THOR) Lower (more...)
-
ANI Pharma (ANIP) Plans Common Stock Offering
-
Roth Capital Starts ANI Pharmaceuticals (ANIP) at Buy

